Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Identifieur interne : 000946 ( PubMed/Corpus ); précédent : 000945; suivant : 000947Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Auteurs : Ronan Roussel ; Michael C. D'Emden ; Miles Fisher ; F Javier Ampudia-Blasco ; Peter Stella ; Florence Bizet ; Anna M G. Cali ; Carol H. WyshamSource :
- Diabetes, obesity & metabolism [ 1463-1326 ] ; 2017.
Abstract
In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDITION 2 (basal insulin plus oral antihyperglycaemic drugs) trials who were previously receiving twice-daily insulin. At randomization, 16.9% and 20.0% of people in EDITION 1 and 2, respectively, were receiving twice-daily basal insulin. Glycated haemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference -0.01%; 95% confidence interval [CI] -0.27 to 0.24] in EDITION 1 and 0.16%; 95% CI -0.25 to 0.57, in EDITION 2). Participants previously receiving twice-daily insulin in EDITION 1 had a lower risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 vs Gla-100 at night (00:00-05:59 hours), but not at any time (24 hours); in EDITION 2 the risk was reduced at night and any time (24 hours). In conclusion, Gla-300 provided similar glycaemic control with less hypoglycaemia compared with Gla-100 in people with T2DM switching from twice-daily to once-daily basal insulin.
DOI: 10.1111/dom.13071
PubMed: 28736942
Links to Exploration step
pubmed:28736942Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).</title><author><name sortKey="Roussel, Ronan" sort="Roussel, Ronan" uniqKey="Roussel R" first="Ronan" last="Roussel">Ronan Roussel</name><affiliation><nlm:affiliation>INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="D Emden, Michael C" sort="D Emden, Michael C" uniqKey="D Emden M" first="Michael C" last="D'Emden">Michael C. D'Emden</name><affiliation><nlm:affiliation>Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, Miles" sort="Fisher, Miles" uniqKey="Fisher M" first="Miles" last="Fisher">Miles Fisher</name><affiliation><nlm:affiliation>Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Ampudia Blasco, F Javier" sort="Ampudia Blasco, F Javier" uniqKey="Ampudia Blasco F" first="F Javier" last="Ampudia-Blasco">F Javier Ampudia-Blasco</name><affiliation><nlm:affiliation>Diabetes Reference Unit, Clinic University Hospital, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Stella, Peter" sort="Stella, Peter" uniqKey="Stella P" first="Peter" last="Stella">Peter Stella</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bizet, Florence" sort="Bizet, Florence" uniqKey="Bizet F" first="Florence" last="Bizet">Florence Bizet</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cali, Anna M G" sort="Cali, Anna M G" uniqKey="Cali A" first="Anna M G" last="Cali">Anna M G. Cali</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wysham, Carol H" sort="Wysham, Carol H" uniqKey="Wysham C" first="Carol H" last="Wysham">Carol H. Wysham</name><affiliation><nlm:affiliation>Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28736942</idno><idno type="pmid">28736942</idno><idno type="doi">10.1111/dom.13071</idno><idno type="wicri:Area/PubMed/Corpus">000946</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000946</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).</title><author><name sortKey="Roussel, Ronan" sort="Roussel, Ronan" uniqKey="Roussel R" first="Ronan" last="Roussel">Ronan Roussel</name><affiliation><nlm:affiliation>INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="D Emden, Michael C" sort="D Emden, Michael C" uniqKey="D Emden M" first="Michael C" last="D'Emden">Michael C. D'Emden</name><affiliation><nlm:affiliation>Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, Miles" sort="Fisher, Miles" uniqKey="Fisher M" first="Miles" last="Fisher">Miles Fisher</name><affiliation><nlm:affiliation>Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Ampudia Blasco, F Javier" sort="Ampudia Blasco, F Javier" uniqKey="Ampudia Blasco F" first="F Javier" last="Ampudia-Blasco">F Javier Ampudia-Blasco</name><affiliation><nlm:affiliation>Diabetes Reference Unit, Clinic University Hospital, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Stella, Peter" sort="Stella, Peter" uniqKey="Stella P" first="Peter" last="Stella">Peter Stella</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bizet, Florence" sort="Bizet, Florence" uniqKey="Bizet F" first="Florence" last="Bizet">Florence Bizet</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cali, Anna M G" sort="Cali, Anna M G" uniqKey="Cali A" first="Anna M G" last="Cali">Anna M G. Cali</name><affiliation><nlm:affiliation>Sanofi, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wysham, Carol H" sort="Wysham, Carol H" uniqKey="Wysham C" first="Carol H" last="Wysham">Carol H. Wysham</name><affiliation><nlm:affiliation>Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Diabetes, obesity & metabolism</title><idno type="eISSN">1463-1326</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDITION 2 (basal insulin plus oral antihyperglycaemic drugs) trials who were previously receiving twice-daily insulin. At randomization, 16.9% and 20.0% of people in EDITION 1 and 2, respectively, were receiving twice-daily basal insulin. Glycated haemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference -0.01%; 95% confidence interval [CI] -0.27 to 0.24] in EDITION 1 and 0.16%; 95% CI -0.25 to 0.57, in EDITION 2). Participants previously receiving twice-daily insulin in EDITION 1 had a lower risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 vs Gla-100 at night (00:00-05:59 hours), but not at any time (24 hours); in EDITION 2 the risk was reduced at night and any time (24 hours). In conclusion, Gla-300 provided similar glycaemic control with less hypoglycaemia compared with Gla-100 in people with T2DM switching from twice-daily to once-daily basal insulin.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28736942</PMID><DateCreated><Year>2017</Year><Month>07</Month><Day>24</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Diabetes, obesity & metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.13071</ELocationID><Abstract><AbstractText>In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDITION 2 (basal insulin plus oral antihyperglycaemic drugs) trials who were previously receiving twice-daily insulin. At randomization, 16.9% and 20.0% of people in EDITION 1 and 2, respectively, were receiving twice-daily basal insulin. Glycated haemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference -0.01%; 95% confidence interval [CI] -0.27 to 0.24] in EDITION 1 and 0.16%; 95% CI -0.25 to 0.57, in EDITION 2). Participants previously receiving twice-daily insulin in EDITION 1 had a lower risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 vs Gla-100 at night (00:00-05:59 hours), but not at any time (24 hours); in EDITION 2 the risk was reduced at night and any time (24 hours). In conclusion, Gla-300 provided similar glycaemic control with less hypoglycaemia compared with Gla-100 in people with T2DM switching from twice-daily to once-daily basal insulin.</AbstractText><CopyrightInformation>© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roussel</LastName><ForeName>Ronan</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-2292-8363</Identifier><AffiliationInfo><Affiliation>INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Emden</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Miles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ampudia-Blasco</LastName><ForeName>F Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Diabetes Reference Unit, Clinic University Hospital, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stella</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sanofi, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizet</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sanofi, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cali</LastName><ForeName>Anna M G</ForeName><Initials>AMG</Initials><AffiliationInfo><Affiliation>Sanofi, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wysham</LastName><ForeName>Carol H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">basal insulin</Keyword><Keyword MajorTopicYN="N">glycaemic control</Keyword><Keyword MajorTopicYN="N">hypoglycaemia</Keyword><Keyword MajorTopicYN="N">insulin analogues</Keyword><Keyword MajorTopicYN="N">phase III study</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28736942</ArticleId><ArticleId IdType="doi">10.1111/dom.13071</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000946 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000946 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28736942
|texte= Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28736942" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |